Investments
303Portfolio Exits
99Funds
19Partners & Customers
2Service Providers
3About Vivo Capital
Vivo Capital, fka Vivo Ventures, is a life-sciences focused venture capital firm formed in 1996 with over $650M under management. The majority of Vivo's investments are in U.S. based companies with therapeutic products in clinical development. Its current portfolio includes more than 60 private and public biotechnology companies in the areas of biopharmaceuticals, specialty pharmaceuticals, and medical devices.
Vivo Capital Headquarter Location
575 High Street Suite 201
Palo Alto, California, 94301,
United States
650-688-0818
Latest Vivo Capital News
May 3, 2022
May 3, 2022 Arrowhead Pharmaceuticals Inc. and Vivo Capital LLC have launched a joint venture named Visirna Therapeutics for RNA interference therapeutics in the greater China market. Arrowhead is the majority shareholder of the new entity, while Vivo invested $60 million in the new entity.
Vivo Capital Investments
303 Investments
Vivo Capital has made 303 investments. Their latest investment was in Visirna Therapeutics as part of their Seed VC on April 4, 2022.
Vivo Capital Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
4/25/2022 | Seed VC | Visirna Therapeutics | $60M | Yes | 3 | |
3/23/2022 | Series A | Ocelot Bio | $36M | Yes | 5 | |
2/7/2022 | Seed VC - III | Rgenta Therapeutics | $8.91M | No | 1 | |
12/8/2021 | Series A | |||||
11/29/2021 | Series A |
Date | 4/25/2022 | 3/23/2022 | 2/7/2022 | 12/8/2021 | 11/29/2021 |
|---|---|---|---|---|---|
Round | Seed VC | Series A | Seed VC - III | Series A | Series A |
Company | Visirna Therapeutics | Ocelot Bio | Rgenta Therapeutics | ||
Amount | $60M | $36M | $8.91M | ||
New? | Yes | Yes | No | ||
Co-Investors | |||||
Sources | 3 | 5 | 1 |
Vivo Capital Portfolio Exits
99 Portfolio Exits
Vivo Capital has 99 portfolio exits. Their latest portfolio exit was AltheaDx on April 04, 2022.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
4/4/2022 | Acquired | 4 | |||
2/23/2022 | IPO | 1 | |||
11/5/2021 | IPO | 12 | |||
Date | 4/4/2022 | 2/23/2022 | 11/5/2021 | ||
|---|---|---|---|---|---|
Exit | Acquired | IPO | IPO | ||
Companies | |||||
Valuation | |||||
Acquirer | |||||
Sources | 4 | 1 | 12 |
Vivo Capital Acquisitions
4 Acquisitions
Vivo Capital acquired 4 companies. Their latest acquisition was Yongrenxin on June 06, 2021.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
|---|---|---|---|---|---|---|
6/6/2021 | Acq - Fin | 1 | ||||
1/6/2021 | ||||||
1/1/2019 | Series A | |||||
12/19/2016 |
Date | 6/6/2021 | 1/6/2021 | 1/1/2019 | 12/19/2016 |
|---|---|---|---|---|
Investment Stage | Series A | |||
Companies | ||||
Valuation | ||||
Total Funding | ||||
Note | Acq - Fin | |||
Sources | 1 |
Vivo Capital Fund History
19 Fund Histories
Vivo Capital has 19 funds, including Vivo Capital Fund IX.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
|---|---|---|---|---|---|
10/30/2019 | Vivo Capital Fund IX | Multi-Stage Venture Capital | Closed | $1,430M | 5 |
5/8/2019 | Vivo Opportunity Co-Invest (W) | $20M | 1 | ||
4/19/2019 | Vivo Opportunity Co-Invest | $80M | |||
9/4/2018 | Vivo Opportunity Fund | ||||
5/26/2016 | Vivo Panda Fund I |
Closing Date | 10/30/2019 | 5/8/2019 | 4/19/2019 | 9/4/2018 | 5/26/2016 |
|---|---|---|---|---|---|
Fund | Vivo Capital Fund IX | Vivo Opportunity Co-Invest (W) | Vivo Opportunity Co-Invest | Vivo Opportunity Fund | Vivo Panda Fund I |
Fund Type | Multi-Stage Venture Capital | ||||
Status | Closed | ||||
Amount | $1,430M | $20M | $80M | ||
Sources | 5 | 1 |
Vivo Capital Partners & Customers
2 Partners and customers
Vivo Capital has 2 strategic partners and customers. Vivo Capital recently partnered with Ascendis Pharma on November 11, 2018.
Date | Type | Business Partner | Country | News Snippet | Sources |
|---|---|---|---|---|---|
11/8/2018 | Partner | Denmark | COPENHAGEN , Denmark -- Ascendis Pharma , a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs , today announced the formation of VISEN Pharmaceuticals , a joint venture with an investor syndicate led by Vivo Capital , to develop , manufacture and commercialize the company 's endocrinology rare disease therapies in Greater China , which includes mainland China , Hong Kong , Macau and Taiwan . | 1 | |
11/8/2018 | Partner |
Date | 11/8/2018 | 11/8/2018 |
|---|---|---|
Type | Partner | Partner |
Business Partner | ||
Country | Denmark | |
News Snippet | COPENHAGEN , Denmark -- Ascendis Pharma , a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs , today announced the formation of VISEN Pharmaceuticals , a joint venture with an investor syndicate led by Vivo Capital , to develop , manufacture and commercialize the company 's endocrinology rare disease therapies in Greater China , which includes mainland China , Hong Kong , Macau and Taiwan . | |
Sources | 1 |
Vivo Capital Service Providers
3 Service Providers
Vivo Capital has 3 service provider relationships
Service Provider | Associated Rounds | Provider Type | Service Type |
|---|---|---|---|
Acq - Fin | Counsel | General Counsel | |
Service Provider | |||
|---|---|---|---|
Associated Rounds | Acq - Fin | ||
Provider Type | Counsel | ||
Service Type | General Counsel |
Partnership data by VentureSource
Vivo Capital Team
17 Team Members
Vivo Capital has 17 team members, including current Managing Partner, Edgar G. Engleman.
Name | Work History | Title | Status |
|---|---|---|---|
Edgar G. Engleman | Managing Partner | Current | |
Edgar G Englemen | Managing Partner | Current | |
Shan Fu | Managing Partner | Current | |
Frank Kung | Managing Partner | Current | |
Chen Yu | Managing Partner | Current |
Name | Edgar G. Engleman | Edgar G Englemen | Shan Fu | Frank Kung | Chen Yu |
|---|---|---|---|---|---|
Work History | |||||
Title | Managing Partner | Managing Partner | Managing Partner | Managing Partner | Managing Partner |
Status | Current | Current | Current | Current | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.